XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Operating Activities:    
Net income (loss) $ 2,224,790 $ (1,222,344)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:    
Depreciation and amortization 417,637 193,809
Warranty provision 44,037 12,361
Inventory obsolescence 133,259 85,435
Share-based compensation 305,820 284,250
Deferred income taxes 557,147 2,867,339
Changes in operating assets and liabilities:    
Accounts receivable, net (3,981,947) 389,434
Inventories, net (1,704,919) (271,543)
Prepaid expenses and other 2,401,303 174,589
Other assets 116,973 (60,614)
Accounts payable (1,847,512) 502,933
Payroll and related (553,919) (656,540)
Warranty settlements (18,078) (22,258)
Accrued and other liabilities 1,021,149 622,485
Net cash (used in) provided by operating activities (884,260) 2,899,336
Investing Activities:    
Purchases of marketable securities (2,318,646) (2,402,346)
Proceeds from maturities of marketable securities 2,316,764 2,401,856
Capital expenditures (299,965) (90,135)
Purchase of Genasys, net of cash and restricted cash acquired (2,246,545)
Net cash used in investing activities (301,847) (2,337,170)
Financing Activities:    
Proceeds from exercise of stock options 45,172 185,718
Repurchase of common stock (2,171,022)
Proceeds from the issuance of unsecured promissory notes 63,144
Payments on promissory notes (17,044) (414,477)
Net cash used in financing activities (2,142,894) (165,615)
Effect of foreign exchange rate on cash (23,938) 335
Net decrease in cash, cash equivalents, and restricted cash (3,352,939) 396,886
Cash, cash equivalents and restricted cash, beginning of period 11,806,074 12,803,887
Cash, cash equivalents and restricted cash, end of period 8,453,135 13,200,773
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:    
Total cash, cash equivalents and restricted cash shown in the consolidated statement of cash flows 11,806,074 12,803,887
Supplemental disclosures of cash flow information:    
Interest paid 2,860 9,186
Noncash investing and financing activities:    
Change in unrealized loss on marketable securities 9,620 (16,868)
Business combinations accounted for as a purchase:    
Fair value of assets acquired 5,520,504
Cash paid or payable (3,011,439)
Liabilities assumed $ 2,509,065